Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Sales & Earnings Generic Drugs

Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch

Liraglutide, Pegfilgrastim Launches In FY26

  • Analysis

Executive Summary

Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Commercial Sales & Earnings Generic Drugs
Latest Headlines

Endeavor Rockets Ahead With IPF Drug After Phase IIa Results

The Looming US Election Weighs On The Minds Of Pharma

Stock Watch: Paradoxical Q1 Earnings Reactions

Bayer’s Menopause Drug Has An Edge But Still Much To Prove

See All
UsernamePublicRestriction

Register

SC150233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By